The short life and rapid death of a novel antihypertensive and antianginal agent

Med J Aust. 1998 Oct 19;169(8):408-9. doi: 10.5694/j.1326-5377.1998.tb126829.x.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Adrenergic beta-Antagonists / adverse effects
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / adverse effects*
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Bradycardia / chemically induced*
  • Calcium Channel Blockers / administration & dosage
  • Calcium Channel Blockers / adverse effects*
  • Conflict of Interest
  • Drug Interactions
  • Drug Therapy, Combination
  • Humans
  • Mibefradil
  • Tachycardia / chemically induced*
  • Tetrahydronaphthalenes / administration & dosage
  • Tetrahydronaphthalenes / adverse effects*

Substances

  • Adrenergic beta-Antagonists
  • Antihypertensive Agents
  • Benzimidazoles
  • Calcium Channel Blockers
  • Tetrahydronaphthalenes
  • Mibefradil